Silvitra is a combination pharmaceutical agent designed to address two of the most prevalent male sexual health concerns: erectile dysfunction and premature ejaculation. By integrating the proven mechanisms of Sildenafil Citrate and Dapoxetine into a single tablet, it offers a comprehensive therapeutic approach aimed at improving both the rigidity and duration of erection, as well as extending intravaginal ejaculatory latency time. This dual-action formulation is intended for adult men experiencing these concurrent conditions, providing a synchronized solution that enhances sexual performance and patient satisfaction. Its development is grounded in clinical evidence supporting the efficacy and safety profile of its active components when used in combination under medical supervision.

Features

• Contains Sildenafil Citrate (100mg) and Dapoxetine Hydrochloride (60mg) as active ingredients
• Oral tablet formulation for convenient administration
• Rapid onset of action, typically within 30-60 minutes post-ingestion
• Designed for on-demand use prior to anticipated sexual activity
• Manufactured under strict pharmaceutical quality control standards
• Available in blister packs for stability and ease of use

Benefits

• Simultaneously addresses both erectile dysfunction and premature ejaculation, reducing the need for multiple medications
• Enhances the ability to achieve and maintain an erection sufficient for satisfactory sexual performance
• Significantly prolongs time to ejaculation, improving sexual control and confidence
• May contribute to improved relationship satisfaction and overall quality of life
• Single-tablet regimen increases treatment adherence compared to multiple drug therapies
• On-demand dosing allows for spontaneity in sexual activity without daily medication commitment

Common use

Silvitra is prescribed for the treatment of erectile dysfunction (ED) concurrent with premature ejaculation (PE) in adult men. It is indicated for patients who experience difficulty achieving or maintaining an erection adequate for sexual intercourse, combined with persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it. The medication is intended for use prior to anticipated sexual activity and is not recommended for continuous daily use. Clinical studies have demonstrated its effectiveness in improving both erectile function and ejaculatory control in men with these comorbid conditions.

Dosage and direction

The recommended dosage is one tablet taken orally approximately 1-3 hours before anticipated sexual activity. The tablet should be swallowed whole with a full glass of water and may be taken with or without food, though high-fat meals may delay the onset of action. The maximum recommended dosing frequency is once per 24-hour period. Healthcare providers should initiate treatment at this standard dosage and adjust based on efficacy and tolerability. Patients should not exceed one tablet in any 24-hour period. The medication requires sexual stimulation to be effective and will not produce an automatic erection.

Precautions

Patients should undergo a thorough medical evaluation before initiating Silvitra therapy to assess cardiovascular status, as sexual activity carries potential cardiac risk. Use with caution in patients with anatomical penile deformity, bleeding disorders, or active peptic ulceration. Caution is advised in patients with a history of syncope or orthostatic hypotension. Patients should avoid alcohol consumption while taking this medication as it may increase the risk of adverse effects such as dizziness, orthostatic hypotension, and syncope. Visual disturbances have been reported with phosphodiesterase type 5 inhibitors; patients should exercise caution when driving or operating machinery.

Contraindications

Silvitra is contraindicated in patients with known hypersensitivity to Sildenafil Citrate, Dapoxetine, or any component of the formulation. Concurrent administration with nitrates or nitric oxide donors in any form is absolutely contraindicated due to the risk of profound hypotension. The medication is contraindicated in patients with severe hepatic impairment, severe cardiovascular disorders where sexual activity is inadvisable, and patients with a history of loss of consciousness or syncope related to sexual activity. Concomitant use with potent CYP3A4 inhibitors or monoamine oxidase inhibitors is contraindicated.

Possible side effects

Common adverse reactions may include headache, flushing, dizziness, nausea, dry mouth, diarrhea, insomnia, and blurred vision. Nasal congestion, dyspepsia, and back pain have been reported. Less frequently, patients may experience orthostatic hypotension, syncope, tachycardia, palpitations, and transient changes in color vision. Serious but rare side effects include priapism, sudden hearing loss, cardiovascular events, and seizures. Patients should discontinue use and seek immediate medical attention if they experience erection lasting more than 4 hours, sudden vision loss, or chest pain during sexual activity.

Drug interactions

Silvitra demonstrates significant interactions with nitrates and nitric oxide donors, resulting in potentially life-threatening hypotension. Concomitant use with alpha-blockers may enhance the hypotensive effects. Potent inhibitors of CYP3A4 (such as ketoconazole, ritonavir, erythromycin) may increase plasma concentrations of both active components. Concurrent administration with other phosphodiesterase type 5 inhibitors is not recommended. The medication may interact with other serotonergic drugs, potentially increasing the risk of serotonin syndrome. Patients taking strong CYP2D6 inhibitors may require dosage adjustment.

Missed dose

As Silvitra is prescribed for on-demand use rather than continuous therapy, the concept of a “missed dose” does not apply in the conventional sense. Patients should take one tablet approximately 1-3 hours before anticipated sexual activity. If sexual activity does not occur after taking the medication, no additional dose should be taken within the same 24-hour period. Patients should not take more than one tablet in any 24-hour period regardless of the number of anticipated sexual encounters.

Overdose

In case of suspected overdose, immediate medical attention should be sought. Symptoms may include severe headache, dizziness, syncope, prolonged erection, and cardiovascular effects. Standard supportive measures should be employed, including monitoring of vital signs and symptomatic treatment. Given the dual mechanism of action, management may require addressing both phosphodiesterase type 5 inhibitor overdose and selective serotonin reuptake inhibitor overdose manifestations. Hemodialysis is not expected to significantly enhance elimination of either component due to high protein binding and extensive tissue distribution.

Storage

Store at room temperature between 15-30°C (59-86°F) in the original packaging to protect from light and moisture. Keep the medication in its original blister packaging until immediately before use to maintain stability. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of any unused medication that has expired or is no longer needed according to local regulations.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Silvitra is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Patients should consult with their physician for proper diagnosis and treatment recommendations. The information provided here may not cover all possible uses, directions, precautions, or adverse effects. Actual product packaging and materials may contain additional or different information than what appears here.

Reviews

Clinical studies have demonstrated that Silvitra significantly improves both erectile function and ejaculatory control compared to placebo. In randomized controlled trials, patients reported improved satisfaction with sexual intercourse, enhanced perception of sexual performance, and reduced personal distress related to sexual function. Many patients appreciate the convenience of the combined formulation compared to taking multiple separate medications. Healthcare providers note the importance of proper patient selection and education regarding appropriate use and potential side effects. Long-term real-world evidence continues to support the efficacy and safety profile established in clinical trials.